Clinical Trial Update: Pharmacodynamic Evaluation of Intramuscular Nalmefene Autoinjector 1.5 mg Compared to Intranasal Narcan 4 mg [Phase 1]

View source ↗

Summary

Phase 1 pharmacodynamic study evaluating an intramuscular nalmefene autoinjector (1.5 mg) versus intranasal naloxone (Narcan) 4 mg for opioid overdose; results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Opioid Overdose

Drugs mentioned

• Intranasal Naloxone (Narcan) 4 mg (Naloxone)
• Nalmefene Autoinjector 1.5 mg (Nalmefene)

Snippet

Sponsor: Purdue Pharma LP | Conditions: Opioid Overdose | Phase 1 | Status: COMPLETED | Results posted: 2025-07-03